Hartmut van Lengerich appointed as Chairman of Moa Technology

  • Hartmut will chair Moa as it develops next-generation herbicides with novel modes of action (MOAs) to tackle the growing challenges in agriculture caused by herbicide-resistant weeds 
  • He has over 30 years’ experience in global strategic and operational roles, including serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently, SVP Global Crop Protection Asset Management at Bayer AG, overseeing $13 billion in worldwide sales

Moa Technology (Moa or the Company), the agricultural biotechnology (agribio) company tackling herbicide-resistant weeds that threaten the world’s food security today announces the appointment of Hartmut van Lengerich as Chairman.

Hartmut is an agricultural economist with over 30 years’ experience in global strategic and operational roles. This includes serving as Bayer Crop Science’s CEO for Canada, Global Head of Cereals, Head of Fungicides and, most recently as SVP for Portfolio- and Asset Management for the Crop Protection Portfolio of Bayer AG, overseeing $13 billion in worldwide sales. Today, Hartmut, who is German, is a senior adviser to Boston Consulting Group.

Hartmut will chair Moa, which was spun out of the University of Oxford in 2017 and now employs more than 60 employees, as it develops and commercialises its pipeline of next-generation synthetic and bioherbicides based on novel modes of action (MOAs).

Innovation to develop next-generation herbicides is urgently needed to overcome the pressing issue of herbicide-resistant weeds, which threaten food security and agricultural productivity, and which are a major problem for growing numbers of farmers across the world. Without effective herbicides, farmers can lose up to 40% of their crop yield as a result of weed growth. The situation is comparable to the threat from antibiotic-resistant bacteria to the efficacy of certain medicines.

Hartmut will formally start as non-executive Chairman on 1 January 2024, but will serve as a strategic advisor and join the board as an observer prior to this. He succeeds Hadyn Parry, who is stepping back from his role on Moa’s board after nearly five years as its chairman after stewarding the company successfully through its formation and early-stage growth. Hadyn was involved in appointing Hartmut to the role and will continue his involvement with Moa as a consultant.

Hartmut van Lengerich, Chairman-Elect of Moa Technology, says: “It is a great time to be joining Moa, as it moves from being a discovery-stage company to one developing and commercialising its strong pipeline of next-generation herbicides. There is clear momentum within the company, and a great opportunity before it. The need for next-generation herbicides across the world is urgent and growing, as the challenges from herbicide-resistant weeds keep increasing. In addition, more rigorous regulatory restrictions add to the innovation need as there are ever fewer herbicide options available to growers around the world. Moa’s unique abilities enable it to identify, understand and develop new herbicides with game-changing speed, accuracy and rigour using its proprietary biotech and AI-based, plant-led discovery engine. It has a vital role to play, and I look forward to helping it develop and evolve.”

Hadyn Parry, outgoing Chairman of Moa Technology, says: “I’m delighted to hand over to an agricultural industry veteran with such remarkable experience and knowledge, and who combines strong commercial instincts and an invaluable understanding of the path to commercialising new products in this area. I have hugely enjoyed chairing Moa as it has grown from a university spin-out to a company that today is backed by leading investors and has a rich pipeline of potential next-generation herbicides and employs dozens of exceptionally talented scientists.”

Virginia Corless, Chief Executive Officer of Moa Technology, says: “We are delighted that Hartmut will be joining Moa as chairman, and I am greatly looking forward to working with him as the company develops its strong pipeline of high potential next generation herbicides. In particular, he will bring immense industry experience and commercial understanding, as well as a remarkable network that will help us bring our essential discoveries to farmers’ fields faster. In addition, we are grateful to Hadyn for his exceptional stewardship of and contribution to the company during the past years.”

 

More news and updates 

Aleta Biotherapeutics and Cancer Research UK announce first patient dosed in ALETA-001 Phase 1/2 clinical trial

The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-cell engager, ALETA-001. ALETA-001 entering the clinic is a critical milestone toward treatment availability to improve CAR T-cell patient response when a complete response is not achieved or maintained.

UKHSA announced as first PACE collaboration to help tackle deadly antimicrobial resistance

Strategic partnership to support AMR innovators

PrecisionLife and Metrodora Institute partner to accelerate diagnosis of Long COVID

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases; targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year

Optibrium enables collaborative design in its StarDrop platform

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking.

BugBiome secures investment for pioneering research in sustainable pest protection

BugBiome raises £310,000 in pre-seed investment from Cambridge Angels and Discovery Park Ventures. Investment enables a £330,000 Engineering Biology Grant from Innovate UK for cutting-edge agri-tech research leveraging the microbiome and engineering biology approaches.

Study reveals POLB 001 could be a $10 billion game changer for cancer patients

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS). Former Amryt Pharma team's arrival supports increasing focus upon Rare and Orphan Diseases

Demand for Golden Triangle lab space surges with highest annual volume since 2015

Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.

New £100 million engineering biology fund

Six new Engineering Biology Mission Hubs and 22 Mission Awards, to transform solutions in areas like vaccine development, textile manufacturing and food production; New investments to unlock potential of engineering biology as part of the wider National Engineering Biology Programme

Pioneer Group’s regeneration plans for Cambridge’s Grafton Centre approved

Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.

Novel drug and software combo tackles hypertension with personalised treatment

Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalised dose optimisation, today announced the publication of a peer-reviewed study in the Journal of the American Heart Association (JAHA) (1).

 

More within